Salivary excretion of mexiletine after bolus intravenous administration in rats
暂无分享,去创建一个
[1] Y. Hayashi,et al. Mandibular and Parotid Salivary Levels of Indomethacin Following Intravenous Administration to Rabbits , 1985, Pharmaceutical Research.
[2] M. Hayashibara,et al. Salivary excretion of mexiletine in normal healthy volunteers , 1991, The Journal of pharmacy and pharmacology.
[3] M. Hayashibara,et al. Comparison of Saliva Stimulation Methods for Noninvasive Therapeutic Drug Monitoring by Using Saliva Samples , 1989 .
[4] Y. Hayashi,et al. Salivary excretion of 5-fluorouracil (5-FU). IV. Dependency of saliva/plasma concentration ratio and salivary clearance on plasma concentration of 5-FU during constant-rate intravenous infusion in rats. , 1989, Journal of pharmacobio-dynamics.
[5] Y. Hayashi,et al. Salivary excretion of 5-fluorouracil (5-FU). III. Non-linear kinetics of salivary excretion of 5-FU following bolus intravenous administration in rats. , 1988, Chemical & pharmaceutical bulletin.
[6] Y. Kanai,et al. Effect of perfused rat mandibular-gland pHI on the ratio of procainamide concentration in saliva to that in venous effluent. , 1988, Biochemical pharmacology.
[7] K. Iwamoto,et al. Mandibular and parotid salivary excretion of procainamide and N‐acetylprocainamide after intravenous administration of procainamide to rats , 1987, The Journal of pharmacy and pharmacology.
[8] Y. Hayashi,et al. Salivary excretion of 5-fluorouracil. I. Fluctuation of the saliva/plasma concentration ratio and salivary clearance in beagle dogs following bolus intravenous administration. , 1985, Chemical & pharmaceutical bulletin.
[9] J. Turgeon,et al. High pressure liquid chromatographic assay for mexiletine in serum. , 1984, Journal of chromatographic science.
[10] Y. Hayashi,et al. Protein binding effects of salivary excretion of phenobarbital in dogs. , 1981, Journal of pharmacobio-dynamics.
[11] Y. Nakase,et al. Excretion of indomethacin into saliva following intravenous administration to dogs. , 1981, Journal of pharmacobio-dynamics.
[12] T Nakagawa,et al. A pharmacokinetic analysis program (multi) for microcomputer. , 1981, Journal of pharmacobio-dynamics.
[13] M. Danhof,et al. Therapeutic Drug Monitoring in Saliva , 1978, Clinical pharmacokinetics.
[14] J. E. Rees. Biopharmaceutical implications of compaction and consolidation in the design of drug dosage forms. , 1978, Bollettino chimico farmaceutico.
[15] P Kellaway,et al. Use of saliva in therapeutic drug monitoring. , 1977, Clinical chemistry.
[16] Beckett Ah,et al. The distribution, metabolism and excretion of mexiletine in man. , 1977 .
[17] A. Beckett,et al. The distribution, metabolism and excretion of mexiletine in man. , 1977, Postgraduate medical journal.
[18] L B Sheiner,et al. Relationship between the pharmacokinetics and pharmacodynamics of procainamide , 1976, Clinical pharmacology and therapeutics.
[19] B. Dvorchik,et al. Pharmacokinetic interpretation of data gathered during therapeutic drug monitoring. , 1976, Clinical chemistry.
[20] J. Karam,et al. Pharmacokinetics of tolbutamide: Prediction by concentration in saliva , 1974, Clinical pharmacology and therapeutics.
[21] D. Julian,et al. Treatment of ventricular arrhythmias with mexiletine (Kö 1173). , 1973, Lancet.